DeepMed Research

Amgen, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1980-01-01

Employees: 26.7K

Market Cap: $175.6B

Website: http://www.amgen.com

Clinical Trials

A Trial to Investigate Teprotumumab (High-concentration Formulation) Subcutaneous Administration in Healthy Adult Non-Japanese and Japanese Participants

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Teprotumumab

First Posted Date: 2024-11-05

Last Posted Date: 2024-11-05

Lead Sponsor: Amgen

Target Recruit Count: 44

Registration Number: NCT06674941

Locations: 🇺🇸
PPD Development, LP, Las Vegas, Nevada, United States

A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Phase 2

Active, not recruiting

Conditions: Type 2 Diabetes Mellitus (T2DM)

Interventions: Drug: Maridebart Cafraglutide
Drug: Placebo

First Posted Date: 2024-10-28

Last Posted Date: 2025-05-16

Lead Sponsor: Amgen

Target Recruit Count: 409

Registration Number: NCT06660173

Locations: 🇵🇱
Centrum Badan Klinicznych Piotr Napora lekarze spolka partnerska, Wroclaw, Poland
🇵🇱
Futuremeds spolka z ograniczona odpowiedzialnoscia, Wroclaw, Poland
🇵🇷
Latin Clinical Trial Center, San Juan, Puerto Rico

and more 92 locations

Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL)

Phase 1

Recruiting

Conditions: B-precursor Acute Lymphoblastic Leukemia

Interventions: Drug: Blinatumomab

First Posted Date: 2024-10-18

Last Posted Date: 2025-02-20

Lead Sponsor: Amgen

Target Recruit Count: 10

Registration Number: NCT06649006

Locations: 🇯🇵
Akita University Hospital, Akita-shi, Akita, Japan
🇯🇵
Kyushu University Hospital, Fukuoka-shi, Fukuoka, Japan
🇯🇵
Kurume University Hospital, Kurume-shi, Fukuoka, Japan

and more 3 locations

A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma

Phase 1

Recruiting

Conditions: Asthma

Interventions: Drug: AMG 691
Drug: Placebo

First Posted Date: 2024-10-15

Last Posted Date: 2025-01-23

Lead Sponsor: Amgen

Target Recruit Count: 124

Registration Number: NCT06637371

Locations: 🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸
Translational Clinical Research LLC, Aventura, Florida, United States
🇺🇸
Prism Research LLC dba Nucleus Network, Saint Paul, Minnesota, United States

Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Phase 1

Recruiting

Conditions: Prostate Cancer

Interventions: Drug: Xaluritamig

First Posted Date: 2024-09-25

Last Posted Date: 2025-04-11

Lead Sponsor: Amgen

Target Recruit Count: 30

Registration Number: NCT06613100

Locations: 🇩🇪
Universitaetsklinikum Hamburg Eppendorf, Hamburg, Germany
🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Washington University, Saint Louis, Missouri, United States

and more 3 locations

A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China

Phase 4

Not yet recruiting

Conditions: Glucocorticoid-induced Osteoporosis

Interventions: Drug: Prolia®

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-19

Lead Sponsor: Amgen

Target Recruit Count: 100

Registration Number: NCT06588153

Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)

Phase 1

Recruiting

Conditions: Extensive Stage Small Cell Lung Cancer

Interventions: Drug: Tarlatamab

First Posted Date: 2024-09-19

Last Posted Date: 2025-03-10

Lead Sponsor: Amgen

Target Recruit Count: 100

Registration Number: NCT06598306

Locations: 🇺🇸
University of Southern California, Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Illinois Chicago, Chicago, Illinois, United States
🇺🇸
Trinity Health Saint Joseph Mercy Ann Arbor, Ann Arbor, Michigan, United States

and more 25 locations

A Phase 2 Study of AMG 193 in Participants With MTAP-deleted Advanced NSCLC

Phase 2

Recruiting

Conditions: MTAP-deleted NSCLC

Interventions: Drug: AMG 193

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-18

Lead Sponsor: Amgen

Target Recruit Count: 200

Registration Number: NCT06593522

Locations: 🇦🇺
Calvary Mater Newcastle Hospital, Waratah, New South Wales, Australia
🇧🇷
Instituto do Cancer Estado SP Icesp, Sao Paulo, São Paulo, Brazil
🇺🇸
City of Hope National Medical Center, Duarte, California, United States

and more 51 locations

AMG 335 Expanded Access Program for IgG4-Related Disease

First Posted Date: 2024-09-10

Last Posted Date: 2024-09-10

Lead Sponsor: Amgen

Registration Number: NCT06590051

Single and Multiple Ascending Dose Study of AMG 513 in Participants With Obesity

Phase 1

Recruiting

Conditions: Cardiometabolic Disease

Interventions: Drug: AMG 513
Drug: Placebo

First Posted Date: 2024-09-05

Last Posted Date: 2025-04-24

Lead Sponsor: Amgen

Target Recruit Count: 80

Registration Number: NCT06585462

Locations: 🇺🇸
Anaheim Clinical Trials, Anaheim, California, United States
🇺🇸
Orange County Research Center, Lake Forest, California, United States
🇺🇸
Fomat Medical Research, Oxnard, California, United States

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy